Dexcom Appoints Teri Lawver as Chief Commercial Officer
January 09 2023 - 8:00AM
Business Wire
DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time
continuous glucose monitoring for people with diabetes, announced
today the appointment of Teri Lawver to the newly created role of
chief commercial officer. In this role, Ms. Lawver will oversee the
global commercial organization with responsibility for global
sales, marketing and customer experience.
Ms. Lawver comes to Dexcom with extensive healthcare and global
business leadership experience. She spent the last two decades at
Johnson & Johnson (J&J) in a variety of leadership roles
across the medical device, consumer med tech, and pharmaceutical
sectors. Most recently, Ms. Lawver was the worldwide vice
president, immunology at Janssen Pharmaceutical Companies of
Johnson & Johnson. During her leadership tenure, the immunology
business underwent a strategic portfolio transformation and grew
annual revenue from $11 billion to $16 billion during a time of
significant market disruption.
“Teri is an exceptional leader who has repeatedly demonstrated
the ability to drive growth and skillfully navigate the global
healthcare landscape,” said Kevin Sayer, chairman, president and
chief executive officer at Dexcom. “In this new role, Teri will
lead Dexcom’s worldwide commercial teams as we build from a
position of strength and look to bring Dexcom CGM to millions of
additional people around the world who can benefit from our
technology.”
“I am thrilled to join Dexcom in the new chief commercial
officer role and guide our talented team at this exciting time in
the company’s history,” said Ms. Lawver. “I believe that the
combination of Dexcom’s extensive market opportunity, leading
technology and commitment to its customers makes this a truly
unique role in healthcare. I look forward to supporting the
company’s continued growth and global expansion.”
About Teri
Lawver
Prior to her role as worldwide vice president, immunology at
Janssen, Ms. Lawver held the position of global vice president,
cardiovascular and metabolism at Janssen. Before joining Janssen,
Ms. Lawver spent six years with J&J Medical Device Companies.
During this time, she served as president of J&J Medical
Companies, Canada, where she had operating and profit and loss
(P&L) responsibility for the full portfolio of J&J Medical
Device and Diagnostics business in Canada. Before that, she was the
worldwide general manager of Animas Corporation, an insulin
delivery company previously acquired by J&J. In this role, she
led the integration and turnaround of the unit. Ms. Lawver joined
J&J at Centocor, a biotech subsidiary, where she held senior
positions in sales and marketing. Before joining J&J, Ms.
Lawver was an associate principal at McKinsey & Company, where
she was a leader in the firm’s healthcare practice. She began her
career as a derivatives analyst at Bloomberg.
Ms. Lawver earned an M.B.A. from Duke University’s Fuqua School
of Business, and a Bachelor of Science degree from Georgetown
University.
About DexCom, Inc.
DexCom, Inc. empowers people to take real-time control of
diabetes through innovative continuous glucose monitoring (CGM)
systems. Headquartered in San Diego, California, and with
operations across Europe and select parts of Asia/Oceania, Dexcom
has emerged as a leader of diabetes care technology. By listening
to the needs of users, caregivers, and providers, Dexcom simplifies
and improves diabetes management around the world. For more
information about Dexcom CGM, visit www.dexcom.com.
© 2023 Dexcom, Inc. Dexcom, Dexcom G6 and Dexcom G7 are
registered trademarks of DexCom, Inc. in the U.S., and may be
registered in other countries. All rights reserved.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230109005172/en/
Media Contact James McIntosh
619-884-2118 james.mcintosh@dexcom.com
Investor Contact Sean
Christensen 858-203-6657 sean.christensen@dexcom.com
DexCom (NASDAQ:DXCM)
Historical Stock Chart
From Sep 2024 to Oct 2024
DexCom (NASDAQ:DXCM)
Historical Stock Chart
From Oct 2023 to Oct 2024